Utilizing a measured approach can increase the probability for identifying search criteria that fulfill a company’s strategy.
Ranan Lachman
Advertisement
Articles by Ranan Lachman
Out-licensing has become a crucial part of most biotech companies' business strategies.
Companies should dig in a more attractive mine where very few other companies are looking.
Advertisement
Latest Updated Articles
Private Industry's Most EligiblePublished: October 1st 2004 | Updated:
The Art and Process of Successful In-LicensingPublished: June 1st 2005 | Updated:
The Top Five Drivers of a Successful Out-licensing ProcessPublished: April 1st 2005 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
